Cubist Systematic Strategies LLC Grows Holdings in Genmab A/S Sponsored ADR $GMAB

Key Points

• Cubist Systematic Strategies LLC increased its stake in Genmab A/S by 112.4%, purchasing an additional 665,893 shares, bringing its total ownership to 1,258,143 shares valued at approximately $24.63 million.
• Genmab A/S reported quarterly earnings of $0.54 per share, exceeding analysts' estimates of $0.39, with a revenue of $925 million, significantly lower than expectations of $5.77 billion.
• Analysts have set a consensus target price of $37.60 for Genmab A/S, with several firms upgrading their ratings to "buy" and others adjusting price objectives up to $46.00.

Cubist Systematic Strategies LLC lifted its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 112.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,258,143 shares of the company's stock after purchasing an additional 665,893 shares during the period. Cubist Systematic Strategies LLC owned 0.20% of Genmab A/S worth $24,634,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in GMAB. Orbis Allan Gray Ltd grew its holdings in shares of Genmab A/S by 102.8% during the first quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company's stock worth $111,816,000 after buying an additional 2,895,179 shares during the last quarter. Deep Track Capital LP acquired a new position in shares of Genmab A/S during the 4th quarter worth approximately $41,740,000. Brandywine Global Investment Management LLC raised its holdings in Genmab A/S by 6.0% in the 1st quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company's stock valued at $33,627,000 after acquiring an additional 97,633 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after buying an additional 938,455 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock valued at $34,509,000 after purchasing an additional 1,038,400 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GMAB has been the topic of several research analyst reports. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. Zacks Research cut Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. HC Wainwright upped their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Friday, August 15th. Finally, Truist Financial boosted their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.60.

Genmab A/S Trading Up 0.3%

GMAB stock traded up $0.09 during mid-day trading on Friday, hitting $27.47. 1,687,178 shares of the company were exchanged, compared to its average volume of 1,447,181. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $27.91. The business has a 50 day simple moving average of $22.68 and a 200-day simple moving average of $21.42. The stock has a market capitalization of $17.62 billion, a PE ratio of 13.81, a price-to-earnings-growth ratio of 7.86 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Equities research analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.